Menstrual Blood HPV Testing Achieves Comparable Accuracy to Clinician Sampling in Large Chinese Study
核心洞察
A large community-based study of 3,068 women in China found that HPV (搜索) testing using menstrual blood collected on sanitary minipads achieved 94.7% sensitivity for detecting high-grade cervical lesions, comparable to 92.1% sensitivity with clinician-collected samples.
Both testing methods demonstrated identical negative predictive values of 99.9% and similar positive predictive values, with minipad testing showing slightly lower specificity at 89.1% versus 90.0% for clinician sampling.
The minipad-based approach could overcome key barriers to cervical cancer (搜索) screening participation, particularly in low-resource settings where cultural concerns and limited medical infrastructure reduce uptake of pelvic examinations.
A groundbreaking study published in The BMJ demonstrates that testing menstrual blood collected on sanitary minipads could provide a reliable, non-invasive alternative to clinician-collected cervical samples for human papillomavirus (搜索) (HPV (搜索)) screening, with comparable accuracy for detecting high-grade cervical lesions.
The large cross-sectional population-based study enrolled 3,068 women aged 20 to 54 years with regular menstrual cycles from four urban and three rural communities in Hubei Province, China, between September 2021 and January 2025. Participants underwent HPV (搜索) testing using both minipad-collected menstrual blood and clinician-collected cervical samples, along with ThinPrep cytology.
Addressing Critical Screening Barriers
Cervical cancer (搜索) remains a leading cause of cancer-related death worldwide despite being largely preventable through screening and early treatment. The disease is linked to approximately 348,000 deaths annually, with 661,000 new cases identified each year, 85% occurring in developing countries. Persistent infection with high-risk HPV (搜索) drives cervical carcinogenesis, making HPV testing the cornerstone of screening programs.
However, clinician-based sampling faces significant barriers in many settings, including limited medical infrastructure, cultural concerns, and discomfort associated with pelvic examinations, which can reduce participation and undermine population-level effectiveness. Self-sampling approaches such as vaginal swabs and cervicovaginal brushes have helped expand screening access, but they are not universally acceptable and can present technical challenges.
Menstrual blood collection using sanitary pads offers a distinct alternative that aligns with routine menstrual practices and avoids vaginal manipulation. Prior small studies suggested strong patient preference and encouraging concordance with clinician sampling, but evidence from large, real-world community populations had been lacking.
Comparable Diagnostic Performance
For detection of cervical intraepithelial neoplasia (搜索) grade 2 or worse (CIN2+ (搜索)), minipad-based HPV (搜索) testing demonstrated a sensitivity of 94.7% (95% CI, 80.9% to 99.1%), comparable to the 92.1% sensitivity observed with clinician-based HPV testing (95% CI, 77.5% to 97.9%; P = 1.00). Specificity was slightly lower with minipad testing at 89.1% (95% CI, 88.0% to 90.2%) compared with 90.0% (95% CI, 88.9% to 91.1%) for clinician sampling (P = 0.001).
Despite this difference, the negative predictive value was identical for both approaches at 99.9% (95% CI, 99.7% to 100.0%; P = 1.00), indicating that a negative result reliably ruled out high-grade disease. Positive predictive values were also similar, resulting in 9.9% for minipad testing versus 10.4% for clinician testing (P = 0.82). Screening efficiency, measured by referrals per CIN2+ (搜索) detected, was comparable at 10.1 versus 9.6 (P = 0.82).
For CIN3+ (搜索) detection, HPV (搜索) testing and cytology methods had comparable sensitivities, with 92.9% for minipad-based testing and 85.7% for clinician-collected samples and cytology. The specificities were 88.5% and 89.4% for minipad-based and clinician-collected samples, respectively.
High Concordance Between Methods
Complete genotype concordance, with both sample types showing the same HPV (搜索) genotypes, was observed in 96.2% of participants, with discordance in only 2.3%. Including partial concordance, where some but not all strains were reported in both samples, 97.7% were concordant, indicating excellent agreement between methods.
HPV (搜索) genotypes and their proportions were similar in both sample types. HPV 16 (搜索) and 18 were identified in 37.5% of minipad-based HPV-positive tests, compared with 31.8% using clinician-collected samples. Multiple HPV strains were identified in 46.8% and 43.3% of samples, respectively.
Implementation Considerations and Future Research
The findings suggest that minipad-collected menstrual blood testing can achieve diagnostic performance comparable to clinician sampling while potentially overcoming key barriers to participation. By integrating screening with routine menstrual hygiene practices, this approach may be particularly valuable in low-resource or culturally sensitive settings where uptake of pelvic examinations remains low.
The authors noted that broader adoption could support efforts to expand cervical cancer (搜索) screening coverage without compromising accuracy, though implementation considerations such as standardization of collection devices and integration into existing screening pathways will be critical.
The investigators identified several areas requiring future research, including direct comparative studies to evaluate "HPV (搜索) testing of menstrual blood against established self-sampling methods (eg, vaginal swabs, cervicovaginal brushes), assessing not only diagnostic accuracy but also accessibility, particularly in under-served populations."
They emphasized that "large scale implementation research must quantify gains from real world screening coverage, with longitudinal studies tracking recruitment, retention, and linkage-to-care rates. Real world trials should measure cost effectiveness and operational barriers in national programmes."
Additionally, future work should validate triage biomarkers for HPV (搜索) testing of menstrual blood to optimize specificity and sensitivity, reducing unnecessary referrals to colposcopy. The protocol showed limitations including a higher total number of positives due to a broader anatomical sampling area, which may detect HPV infections beyond the cervix and could increase false-positive results and unnecessary referrals.
The authors commented that this approach could encourage women and girls to educate themselves about their health and promote preventive behaviors, noting that "this psychological alert effect can transform screening from passive surveillance to active health management."